JP2010511059A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010511059A5 JP2010511059A5 JP2009539434A JP2009539434A JP2010511059A5 JP 2010511059 A5 JP2010511059 A5 JP 2010511059A5 JP 2009539434 A JP2009539434 A JP 2009539434A JP 2009539434 A JP2009539434 A JP 2009539434A JP 2010511059 A5 JP2010511059 A5 JP 2010511059A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- cycloalkyl
- substituted
- het
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims 65
- 125000000753 cycloalkyl group Chemical group 0.000 claims 39
- 125000003118 aryl group Chemical group 0.000 claims 28
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 125000001424 substituent group Chemical group 0.000 claims 10
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 8
- 150000002367 halogens Chemical class 0.000 claims 8
- 229910052760 oxygen Inorganic materials 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 7
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- -1 or het Chemical group 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 229910052799 carbon Inorganic materials 0.000 claims 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000002877 alkyl aryl group Chemical group 0.000 claims 5
- 125000000304 alkynyl group Chemical group 0.000 claims 5
- 125000000623 heterocyclic group Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003710 aryl alkyl group Chemical group 0.000 claims 4
- 125000001589 carboacyl group Chemical group 0.000 claims 4
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 229960000684 cytarabine Drugs 0.000 claims 4
- 229960004679 doxorubicin Drugs 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 3
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 3
- 125000004399 C1-C4 alkenyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 125000004093 cyano group Chemical group *C#N 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 210000000170 cell membrane Anatomy 0.000 claims 2
- 238000011254 conventional chemotherapy Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 229940080818 propionamide Drugs 0.000 claims 2
- SNOOUWRIMMFWNE-UHFFFAOYSA-M sodium;6-[(3,4,5-trimethoxybenzoyl)amino]hexanoate Chemical compound [Na+].COC1=CC(C(=O)NCCCCCC([O-])=O)=CC(OC)=C1OC SNOOUWRIMMFWNE-UHFFFAOYSA-M 0.000 claims 2
- 125000003396 thiol group Chemical group [H]S* 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 claims 1
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 1
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N Biguanide Chemical compound NC(N)=NC(N)=N XNCOSPRUTUOJCJ-UHFFFAOYSA-N 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 125000004450 alkenylene group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 125000001118 alkylidene group Chemical group 0.000 claims 1
- 125000005135 aryl sulfinyl group Chemical group 0.000 claims 1
- 125000005228 aryl sulfonate group Chemical class 0.000 claims 1
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims 1
- 125000004421 aryl sulphonamide group Chemical group 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 125000000319 biphenyl-4-yl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 230000000366 juvenile effect Effects 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 125000004430 oxygen atom Chemical group O* 0.000 claims 1
- 125000001476 phosphono group Chemical group [H]OP(*)(=O)O[H] 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- TXHPORRYUKITDP-UHFFFAOYSA-N sulfamoylsulfamic acid Chemical compound NS(=O)(=O)NS(O)(=O)=O TXHPORRYUKITDP-UHFFFAOYSA-N 0.000 claims 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 125000004434 sulfur atom Chemical group 0.000 claims 1
- 230000037396 body weight Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 2
- 231100000682 maximum tolerated dose Toxicity 0.000 description 2
- BMGQWWVMWDBQGC-IIFHNQTCSA-N midostaurin Chemical compound CN([C@H]1[C@H]([C@]2(C)O[C@@H](N3C4=CC=CC=C4C4=C5C(=O)NCC5=C5C6=CC=CC=C6N2C5=C43)C1)OC)C(=O)C1=CC=CC=C1 BMGQWWVMWDBQGC-IIFHNQTCSA-N 0.000 description 2
- 229950010895 midostaurin Drugs 0.000 description 2
- 241000288906 Primates Species 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86744806P | 2006-11-28 | 2006-11-28 | |
| US60/867,448 | 2006-11-28 | ||
| US89108807P | 2007-02-22 | 2007-02-22 | |
| US60/891,088 | 2007-02-22 | ||
| PCT/US2007/085579 WO2008067280A2 (en) | 2006-11-28 | 2007-11-27 | Combination of iap inhibitors and flt3 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010511059A JP2010511059A (ja) | 2010-04-08 |
| JP2010511059A5 true JP2010511059A5 (enExample) | 2011-01-20 |
| JP5394249B2 JP5394249B2 (ja) | 2014-01-22 |
Family
ID=39386468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009539434A Expired - Fee Related JP5394249B2 (ja) | 2006-11-28 | 2007-11-27 | Ｉａｐ阻害剤とｆｌｔ３阻害剤の組合せ剤 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8492429B2 (enExample) |
| EP (1) | EP2089024B1 (enExample) |
| JP (1) | JP5394249B2 (enExample) |
| KR (1) | KR20090087094A (enExample) |
| AT (1) | ATE509629T1 (enExample) |
| AU (1) | AU2007325280B2 (enExample) |
| BR (1) | BRPI0719543A2 (enExample) |
| CA (1) | CA2670498A1 (enExample) |
| CO (1) | CO6210722A2 (enExample) |
| EC (1) | ECSP099472A (enExample) |
| GT (1) | GT200900142A (enExample) |
| IL (1) | IL198551A0 (enExample) |
| MA (1) | MA30966B1 (enExample) |
| MX (1) | MX2009005621A (enExample) |
| NO (1) | NO20092417L (enExample) |
| PL (1) | PL2089024T3 (enExample) |
| PT (1) | PT2089024E (enExample) |
| RU (1) | RU2456983C2 (enExample) |
| TN (1) | TN2009000206A1 (enExample) |
| WO (1) | WO2008067280A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2607940C (en) | 2005-05-18 | 2009-12-15 | Aegera Therapeutics Inc. | Bir domain binding compounds |
| WO2007048224A1 (en) | 2005-10-25 | 2007-05-03 | Aegera Therapeutics Inc. | Iap bir domain binding compounds |
| TWI543988B (zh) | 2006-03-16 | 2016-08-01 | 科學製藥股份有限公司 | 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物 |
| MY159563A (en) | 2006-05-16 | 2017-01-13 | Pharmascience Inc | Iap bir domain binding compounds |
| US20100056495A1 (en) * | 2006-07-24 | 2010-03-04 | Tetralogic Pharmaceuticals Corporation | Dimeric iap inhibitors |
| ES2882855T3 (es) * | 2008-05-16 | 2021-12-02 | Dana Farber Cancer Inst Inc | Inmunomodulación por inhibidores de IAP |
| US20100317593A1 (en) * | 2009-06-12 | 2010-12-16 | Astrazeneca Ab | 2,3-dihydro-1h-indene compounds |
| NZ602368A (en) | 2010-02-12 | 2014-10-31 | Pharmascience Inc | Iap bir domain binding compounds |
| US20140243276A1 (en) | 2011-09-30 | 2014-08-28 | Tetralogic Pharmaceuticals Corporation | Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer) |
| ES2982449T3 (es) | 2013-06-25 | 2024-10-16 | Walter & Eliza Hall Inst Medical Res | Miméticos Smac para su uso en el tratamiento de una infección persistente por VIH |
| CA2974651A1 (en) | 2014-01-24 | 2015-07-30 | Children's Hospital Of Eastern Ontario Research Institute Inc. | Smc combination therapy for the treatment of cancer |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| PE20212153A1 (es) | 2019-02-22 | 2021-11-09 | Hanmi Pharm Ind Co Ltd | Composicion farmaceutica que comprende un inhibidor de flt3 y un agente hipometilante para tratar la leucemia mieloide aguda |
| CA3130244A1 (en) | 2019-02-22 | 2020-08-27 | Hanmi Pharm. Co., Ltd. | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| KR20200102948A (ko) | 2019-02-22 | 2020-09-01 | 한미약품 주식회사 | Flt3 저해제 및 iap 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물 |
| SG11202110742TA (en) | 2019-04-02 | 2021-10-28 | Aligos Therapeutics Inc | Compounds targeting prmt5 |
| KR20210002015A (ko) | 2019-06-27 | 2021-01-06 | 한미약품 주식회사 | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| HUP2200468A1 (hu) | 2020-04-29 | 2023-03-28 | X Chem Zrt | IAP antagonisták és gyógyászati alkalmazásuk |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1453661A1 (ru) * | 1972-11-17 | 1989-10-30 | Всесоюзный научно-исследовательский химико-фармацевтический институт им.Серго Орджоникидзе | Противоопухолевое средство "продимин |
| US20060128632A1 (en) | 2002-07-02 | 2006-06-15 | Sharma Sushil K | Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap) |
| WO2005097791A1 (en) | 2004-04-07 | 2005-10-20 | Novartis Ag | Inhibitors of iap |
| CN101340947B (zh) | 2005-12-20 | 2012-09-05 | 诺瓦提斯公司 | Iap-抑制剂和紫杉烷7的组合 |
| PE20110224A1 (es) * | 2006-08-02 | 2011-04-05 | Novartis Ag | PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO |
-
2007
- 2007-11-27 KR KR1020097013350A patent/KR20090087094A/ko not_active Abandoned
- 2007-11-27 JP JP2009539434A patent/JP5394249B2/ja not_active Expired - Fee Related
- 2007-11-27 EP EP07868853A patent/EP2089024B1/en active Active
- 2007-11-27 WO PCT/US2007/085579 patent/WO2008067280A2/en not_active Ceased
- 2007-11-27 AT AT07868853T patent/ATE509629T1/de active
- 2007-11-27 AU AU2007325280A patent/AU2007325280B2/en not_active Ceased
- 2007-11-27 MX MX2009005621A patent/MX2009005621A/es active IP Right Grant
- 2007-11-27 RU RU2009124590/15A patent/RU2456983C2/ru not_active IP Right Cessation
- 2007-11-27 PT PT07868853T patent/PT2089024E/pt unknown
- 2007-11-27 PL PL07868853T patent/PL2089024T3/pl unknown
- 2007-11-27 US US12/516,062 patent/US8492429B2/en not_active Expired - Fee Related
- 2007-11-27 CA CA002670498A patent/CA2670498A1/en not_active Abandoned
- 2007-11-27 BR BRPI0719543-5A patent/BRPI0719543A2/pt not_active IP Right Cessation
-
2009
- 2009-05-04 IL IL198551A patent/IL198551A0/en unknown
- 2009-05-22 TN TNP2009000206A patent/TN2009000206A1/fr unknown
- 2009-05-27 GT GT200900142A patent/GT200900142A/es unknown
- 2009-06-03 MA MA31946A patent/MA30966B1/fr unknown
- 2009-06-24 NO NO20092417A patent/NO20092417L/no not_active Application Discontinuation
- 2009-06-25 CO CO09066298A patent/CO6210722A2/es not_active Application Discontinuation
- 2009-06-26 EC EC2009009472A patent/ECSP099472A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010511059A5 (enExample) | ||
| KR102456572B1 (ko) | 벤질 페닐 에테르 유도체, 그 제조 방법 및 약제학적 조성물 및 용도 | |
| AU2017309199B2 (en) | Amino pyrimidine SSAO inhibitors | |
| US8338414B2 (en) | Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient | |
| JP6198721B2 (ja) | Ｈｃｖ感染症を治療するのに有用な置換されたアリファン、シクロファン、ヘテラファン、ヘテロファン、ヘテロ−ヘテラファンおよびメタロセン | |
| CN118591540A (zh) | 包含环状2-氨基-3-氰基噻吩的kras降解化合物 | |
| WO2022109396A1 (en) | Compounds and uses thereof | |
| WO2021155321A2 (en) | Compounds and uses thereof | |
| RU2009118487A (ru) | Органические соединения | |
| EP4132529A1 (en) | Compounds and uses thereof | |
| ES2899852T3 (es) | Compuestos de N-(4-hidroxi-4-metil-ciclohexil)-4-fenil-bencenosulfonamida y N-(-4-hidroxi-4-metil-ciclohexil)-4-(2-piridil)-bencenosulfonamida y su uso terapéutico | |
| CA2535242A1 (en) | Use of c-kit inhibitors for treating type ii diabetes | |
| WO2021022163A2 (en) | Compounds and uses thereof | |
| US9701711B2 (en) | Modulators of protease activated receptors | |
| HUT74453A (en) | 2,9-diamino- and 2-amino-8-carbamoyl-4-hydroxy-alkane-carboxylic acid derivatives, process for preparing them, their intermediates, use and pharmaceutical compns. contg. the said compds. | |
| KR20090083412A (ko) | 급성 골수성 백혈병의 치료를 위한 ｉａｐ 억제제의 용도 | |
| AU2017255525A1 (en) | 6-aminopyridin-3-yl thiazoles as modulators of rorgammat | |
| JP2006525312A (ja) | 脳虚血を治療するためのチロシンキナーゼ阻害剤の使用方法 | |
| JPWO2019022223A1 (ja) | 環状アミン誘導体及びその医薬用途 | |
| TW593330B (en) | Orally active A1 adenosine receptor agonists | |
| WO2011057220A2 (en) | Compositions and methods for treating lymphoma | |
| AU2022314729A1 (en) | Sulfonimidamde compounds and uses thereof | |
| KR101693326B1 (ko) | 3,4-디히드로퀴나졸린 유도체 및 그를 포함하는 복합제 | |
| MD3288949T2 (ro) | Derivați de aminohidrothiazină fuzionați cu tetrahidrofuran utili în tratamentul bolii Alzheimer | |
| BR112020001588A2 (pt) | agente terapêutico ou um agente preventivo para alopecia areata |